Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain

NCT02934061 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Low Back Pain

Interventions

DEVICE: Tizaspray® administered intranasally
DRUG: Sirdalud® 2 mg tablets administered

Sponsor

MDM S.p.A.

Collaborators

[object Object]
[object Object]